Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LGND Ligand Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: LGND
Price (delayed)
$104.54
Market cap
$2.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.2
Enterprise value
$1.97B
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.
Highlights
The gross profit has surged by 55% year-on-year and by 8% since the previous quarter
The revenue has surged by 53% year-on-year and by 9% since the previous quarter
Ligand Pharmaceuticals's quick ratio has shrunk by 78% YoY and by 47% QoQ
The equity has declined by 4.2% since the previous quarter
Key stats
What are the main financial stats of LGND
Market
Valuations
Earnings
Shares outstanding
19.29M
Market cap
$2.02B
Enterprise value
$1.97B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.53
Price to sales (P/S)
11.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.87
Revenue
$181.49M
Gross profit
$168.45M
Operating income
-$61.81M
Net income
-$132.62M
EBIT
-$157.35M
EBITDA
-$119.89M
Free cash flow
$50.94M
Per share
Balance sheet
Liquidity
EPS
-$7.2
EPS diluted
-$7.16
Free cash flow per share
$2.65
Book value per share
$41.31
Revenue per share
$9.46
TBVPS
$28.42
Total assets
$905.44M
Total liabilities
$109.9M
Debt
$4.45M
Equity
$795.53M
Working capital
$250.63M
Debt to equity
0.01
Current ratio
5.27
Quick ratio
4.22
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
-66.1%
Gross margin
92.8%
Net margin
-73.1%
Operating margin
-34.1%
Return on assets
-14.5%
Return on equity
-16.4%
Return on invested capital
-34%
Return on capital employed
-18.6%
Return on sales
-86.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LGND stock price
How has the Ligand Pharmaceuticals stock price performed over time
Intraday
1.03%
1 week
0.06%
1 month
-0.08%
1 year
22.96%
YTD
-2.44%
QTD
-0.57%
Financial performance
How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$181.49M
Gross profit
$168.45M
Operating income
-$61.81M
Net income
-$132.62M
Gross margin
92.8%
Net margin
-73.1%
The net margin has plunged by 190% YoY
The company's operating income has shrunk by 173% QoQ
Ligand Pharmaceuticals's operating margin has shrunk by 153% QoQ
The gross profit has surged by 55% year-on-year and by 8% since the previous quarter
Price vs fundamentals
How does LGND's price correlate with its fundamentals
Growth
What is Ligand Pharmaceuticals's growth rate over time
Valuation
What is Ligand Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.53
P/S
11.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.87
LGND's P/B is 10% higher than its 5-year quarterly average of 2.3 and 10% higher than its last 4 quarters average of 2.3
The equity has declined by 4.2% since the previous quarter
The revenue has surged by 53% year-on-year and by 9% since the previous quarter
The price to sales (P/S) is 14% higher than the 5-year quarterly average of 9.7 but 4.7% lower than the last 4 quarters average of 11.6
Efficiency
How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's ROIC has plunged by 197% YoY
Ligand Pharmaceuticals's return on sales has shrunk by 184% YoY
Dividends
What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LGND.
Financial health
How did Ligand Pharmaceuticals financials performed over time
Ligand Pharmaceuticals's quick ratio has shrunk by 78% YoY and by 47% QoQ
LGND's current ratio has dropped by 75% year-on-year and by 41% since the previous quarter
The debt is 99% less than the equity
The debt has contracted by 37% from the previous quarter and by 28% YoY
The equity has declined by 4.2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.